Amaryl: Combination Drug Treatment for Type II Diabetes

Posts Related to Amaryl: Combination Drug Treatment for Type II Diabetes

• Glimepiride

  Drug Approvals (British Approved Name, US Adopted Name, rINN) INNs in other languages (French, Latin, and Spanish): Synonyms: Glimepirid; Glimepirida; Glimepiridi; Glimepiridum; Hoe-490 BAN: Glimepiride USAN: Glimepiride INN: Glimepiride [rINN (en)] INN: Glimepirida [rINN (es)] INN: Glimépiride [rINN (fr)] INN: Glimepiridum [rINN (la)] INN: Глимепирид [rINN (ru)] Chemical name: 1-({p-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl}sulfonyl)-3-(trans-4-methylcyclohexyl)urea Molecular formula: C24H34N4O5S =490.6 CAS: ...

• Insulin Therapy for Type 2 Diabetes

  The benefits of intensive glycemic control in patients with type 2 diabetes have focused greater attention on the use of various combinations of insulin and oral antidiabetic drugs (Table 3). Such combinations not only utilize complementary mechanisms of action but also lower doses of both insulin and oral agents, thereby minimizing the risk of adverse ...

• Managing Diabetic Patients who have Renal Failure. Part 5

  Patient-Specific Considerations New antidiabetic agents were approved for the U.S. market. They are metformin, acarbose and glimepiride. Precautions associated with their use in the patient with renal insufficiency will now be described. Metformin (Glucophage): The biguanide hypoglycemic agent metformin (Glucophage) is approved for use in the treatment of diabetes mellitus. Metformin is indicated for use ...

• Type 2 Diabetes: Antidiabetic Agents

  All patients with type 1 diabetes are dependent on exogenous insulin administration, whereas patients with type 2 diabetes have a relative, not an absolute, insulin deficiency. If monitoring and lifestyle changes alone do not produce adequate glucose control of type 2 diabetes, oral antidiabetic agents will be prescribed. Diet, exercise, and optimal use of oral ...

• Insulin Resistance: Insulin Sensitizers in Clinical Practice

  The two thiazolidinediones approved for use in type 2 diabetes are rosiglitazone and pioglitazone. These agents became available in 1999 and are approved as monotherapy and in combination with sulfonylurea or metformin for the treatment of type 2 diabetes. Pioglitazone is also approved in combination with insulin. Troglitazone (Rezulin),which was the first member of this ...